Organization | Groupe Hospitalier Public Sud Oise

Groupe Hospitalier Public Sud Oise Report issue

Academic/Hospital Phase 2

Organization Overview

First Clinical Trial

2000

NCT00010075

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2019

Timeline

NOW

Now

Alternative names

C.H. Senlis | C.H. Sud Francilien, Corbeil-Essonnes, France | groupe hospitalier public sud de l'oise

Active Ingredients

Drugs in Phase 2 Trials (9)

cyclophosphamide (cytoxan) (1 trial)

doxorubicin (Doxil) (1 trial)

fluorouracil (efudex) (1 trial)

lenalidomide (revlimid) (1 trial)

leucovorin (1 trial)

mitoxantrone (novantrone) (1 trial)

prednisone (meticorten) (1 trial)

rituximab (rituxan) (2 trials)

vincristine (oncovin) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Breast Neoplasms (Phase 2)

Immunoblastic Lymphadenopathy (Phase 2)

Lymphoma (Phase 2)

Lymphoma, B-Cell (Phase 2)

Lymphoma, Large B-Cell, Diffuse (Phase 2)

Overview

Highest Phase: Phase 2
# of Trials: 3
# of Trial APIs: 9